Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company, is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. Lori Lyons-Williams, the company's president and CEO, will detail the progress of Abdera's clinical trials, including the first-in-human Phase 1 clinical trial for ABD-147, aimed at treating small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Additionally, Abdera plans to share preclinical data for ABD-320, currently in IND-enabling studies, and provide updates on its expanded radiotherapeutic capabilities.
ABD-147 is a targeted radiopharmaceutical therapy designed to deliver Actinium-225 to solid tumors expressing delta-like ligand 3 (DLL3), a protein critical for neuroendocrine cell differentiation in the lungs. DLL3 is highly expressed in certain high-grade neuroendocrine carcinomas, making it a compelling target for treatment. The U.S. FDA has granted Fast Track and Orphan Drug Designations to ABD-147 for treating extensive stage small cell lung cancer and neuroendocrine carcinoma, respectively.
ABD-320, another therapy under development, targets an undisclosed protein prevalent in several cancer types, aiming to deliver Actinium-225 to solid tumors while minimizing systemic radiotoxicities. This therapy represents a novel approach to addressing its target, leveraging Abdera's proprietary ROVEr™ platform for precision radiopharmaceutical development.
Abdera Therapeutics, headquartered in South San Francisco, CA, with offices in Vancouver, British Columbia, focuses on developing precision radiopharmaceuticals for cancer treatment using its advanced antibody engineering platform.
